ULK1 inhibitors and methods using same
In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
2. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
3. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
4. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
5. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
6. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
7. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
8. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
9. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
10. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
11. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
12. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:
13. A compound or a pharmaceutically acceptable salt thereof having the structure:
14. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:
and
at least one pharmaceutically acceptable additive.
15. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:
16. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:
17. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:
18. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:
19. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof has the structure:
20. A pharmaceutical composition comprising:
a compound or a pharmaceutically acceptable salt thereof having the structure:
and
at least one pharmaceutically acceptable additive.